This study was aimed to explore the influence of
brucine on the early differentiation of osteoblasts and the metabolic pathway of osteoclast in
multiple myeloma (MM) and to compare the effects of
brucine and
bortezomib on MM. The half inhibitory concentration (IC(50)) of
brucine and
bortezomib on MM cell line U266 was determined by MTT method; the
mRNA levels of
alkaline phosphatase (ALP),
osteocalcin (OC),
osteoprotegerin (OPG) and
osteoprotegerin ligand (RANKL) were detected by RT-PCR after the supernatant of cultured U266 cells was added into the culture system for inducing the differentiation of osteoblast line MC3T3-E1 and culturing. The results showed that the IC(50)of
bortezomib and
brucine on U266 cells for 48 hours were 22.4 nmol/L and 0.16 mg/ml respectively. As compared with osteoblasts treated by supernatant of cultured MM cells alone, the
mRNA levels of ALP, OC and OPG in osteoblasts treated by
brucine combined with supernatant of cultured MM cells were enhanced (p < 0.05), while the RANKL
mRNA level was lowered (p < 0.05), moreover the enhanced and lowered degree also was large (p < 0.05). It is concluded that the influence of
brucine on metabolism of osteoblasts and osteoclasts in MM may be realized through the regulation of osteoclasts by osteoblasts. The therapeutic efficacy of
brucine on MM is superior to
bortezomib.